Researchers are advancing their understanding of how autism develops in the brain, potentially paving the way for new treatments. A study utilizing artificial intelligence and lab-grown brain tissue has mapped the genetic mutations associated with autism, revealing how they can rewire brain functions, reports BritPanorama.
The molecular map was published in the journal Science and offers insights into the biological underpinnings of autism, which has long presented challenges in terms of effective treatment development. Dr. Nevan Krogan, one of the study’s authors and a professor at the University of California, San Francisco, emphasized the potential for drug discovery stemming from this research.
According to Krogan, “You need this insight to ultimately develop drugs, and we’ve generated a map now that is providing essentially the molecular underpinnings of autism and pointing us in a multitude of different directions for ultimate drug discovery.” He noted that the hope is to use this mapping as a foundation for developing the first effective autism treatments.
Previous efforts to identify treatments for autism faced complications due to the involvement of over 250 genetic mutations associated with the spectrum disorder. The new study highlights how many of these genetic variants interact and influence protein functions within the brain through 1,800 identified protein-protein interactions, yielding 87% of these interactions as previously undocumented.
Dr. Krogan explained, “When you have the genes and the mutations, that’s just a list. That’s a parts list. What you need to do is have a wiring diagram of that parts list.” His team is already working on three new therapy programs inspired by these findings using the insights gained.
Building an autism map
The mapping work revealed the ways autism-related genetic mutations affect how proteins interact, establishing a clearer understanding of their roles in brain development. This research utilized an artificial intelligence tool named AlphaFold to prioritize genetic mutations for study within lab-grown brain organoids.
Krogan asserted that the study presents the largest autism map ever created, a significant advance that may contribute not only to autism therapies but also to understanding conditions like schizophrenia and other neuropsychiatric disorders. The findings point towards possible interventions that could stabilize problematic protein interactions rather than trying to address each mutation individually.
Watershed moment for autism
While the study provides a promising roadmap for identifying therapies, its applicability may be most relevant to individuals with profound autism, constituting approximately 30% of autism spectrum disorder cases. Dr. Krogan acknowledged that these insights are primarily aimed at those requiring extensive care.
Experts in the field have welcomed the findings. Alison Singer, president of the nonprofit Autism Science Foundation, noted, “Today’s study shows where different autism genes converge on shared biological pathways, and those shared pathways could ultimately give us therapeutic targets relevant to much larger groups of autistic people.”
Nonetheless, translating these breakthroughs into effective treatments will require significant time and effort. Dr. Andy Shih, chief science officer at Autism Speaks, warned that it might take years before any new therapies emerge from this research.
As autism continues to gain prominence in health discussions, the evolving landscape of research outlined by this study reflects a shifting focus towards understanding and addressing the biological foundations of the disorder. The path forward appears more illuminated than ever, though challenges remain in applying these advancements clinically.
